Ligand Screening for E3 Ligase

Inquiry

Ligand Screening for E3 Ligase

CD ComputaBio is a leading provider of computational biology services, specializing in ligand screening for E3 ligase. Our team of experienced scientists and cutting-edge technology allow us to deliver high-quality results to our clients in the pharmaceutical and biotechnology industries.

Introduction of Ligand Screening for E3 Ligase

E3 ligases are essential components of the ubiquitin-proteasome system, a crucial cellular pathway for protein degradation. They play a critical role in regulating various cellular processes, including cell cycle control, signal transduction, and DNA repair. Dysregulation of E3 ligases has been implicated in the development and progression of numerous diseases, making them attractive targets for drug discovery. By screening libraries of compounds, researchers can identify potential drug candidates that can selectively bind to and modulate the activity of specific E3 ligases.

Fig 1. Ligand Screening for E3 LigaseFigure 1. Ligand Screening for E3 Ligase. (Johansson H, et al.2019)

Our Service

Fig 2. Virtual screening for E3 Ligase

Virtual screening

We use state-of-the-art computational methods to screen libraries of small molecules and identify potential drug candidates that can bind to and modulate the activity of E3 ligases.

Fig 3. Molecular docking for E3 Ligase

Molecular docking

We use molecular docking simulations to predict the binding affinity and binding mode of small molecules to E3 ligases, allowing us to prioritize potential drug candidates for further study.

Fig 4. Pharmacophore modeling for E3 Ligase

Pharmacophore modeling

We use pharmacophore modeling to identify key structural features that are essential for the binding of small molecules to E3 ligases, helping us design novel drug candidates with improved potency and selectivity.

Fig 5. Quantitative Structure-Activity Relationship (QSAR) Modelling for E3 Ligase

Quantitative Structure-Activity Relationship (QSAR) Modelling

Predictive models can be developed to understand the relationship between the chemical structure of a ligand and its biological activity against E3 ligases.

The process of Ligand Screening for E3 Ligase

Project Consultation - Understanding the specific requirements and objectives of our clients.

Computational Analysis - Employing a combination of virtual screening, molecular modeling, and simulation techniques.

Hit Identification - Identifying potential ligands with the desired binding properties.

Hit Validation - Performing in-depth analyses to validate the efficacy and specificity of selected ligands.

Report Generation - Delivering comprehensive reports with detailed findings and recommendations for further experimental validation.

Approach to Ligand Screening for E3 Ligase

Structure-based drug design

We use the three-dimensional structure of the target E3 ligase to design novel drug candidates with improved potency and selectivity.

Ligand-based drug design

We use the chemical and structural properties of known ligands to design novel drug candidates that can selectively bind to and modulate the activity of the target E3 ligase.

Fragment-based drug design

We use fragment-based screening approaches to identify small molecules that can bind to the target E3 ligase and serve as starting points for drug discovery.

Advantages of Our Services

Precision

By leveraging advanced algorithms and modeling techniques, we identify ligands with high binding affinity and selectivity for E3 ligases.

Cost-Effectiveness

Our services offer a cost-effective alternative to traditional experimental screening methods, minimizing experimental errors and redundancies.

Customization

We tailor our services to meet the specific needs and objectives of each client, providing personalized solutions for diverse drug discovery projects.

Ligand screening for E3 ligase is a crucial step in drug discovery efforts targeting these important enzymes. At CD ComputaBio, we offer comprehensive ligand screening services for E3 ligase to support our clients in the pharmaceutical and biotechnology industries. Our team of experts, cutting-edge technology, and customized solutions make us the ideal partner for your ligand screening needs. Contact us today to learn more about our services and how we can help you accelerate your drug discovery efforts.

References:

  1. Kohlbacher S M, Langer T, Seidel T. QPHAR: Quantitative pharmacophore activity relationship: Method and validation. Journal of cheminformatics, 2021, 13: 1-14.
  2. Alamri M A. Pharmacoinformatics and molecular dynamic simulation studies to identify potential small-molecule inhibitors of WNK-SPAK/OSR1 signaling that mimic the RFQV motifs of WNK kinases[J]. Arabian Journal of Chemistry, 2020, 13(4): 5107-5117.
  3. Johansson H, Isabella Tsai Y C, Fantom K, et al. Fragment-based covalent ligand screening enables rapid discovery of inhibitors for the RBR E3 ubiquitin ligase HOIP[J]. Journal of the American Chemical Society, 2019, 141(6): 2703-2712.
* For Research Use Only.
Inquiry
logo
Give us a free call

Send us an email

Copyright © CD ComputaBio. All Rights Reserved.
  • twitter
Top